Homozygous Familial Hypercholesterolemia Market is expected to reach US$ 101.8 million by 2030 | Major Companies - AstraZeneca, Viatris Inc., Accord Healthcare.

Market Size and Growth:

The Global Homozygous Familial Hypercholesterolemia Market size reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030, growing with a CAGR of 2.5% during the forecast period 2024-2031.

The Homozygous Familial Hypercholesterolemia Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/homozygous-familial-hypercholesterolemia-market?sz

The Homozygous Familial Hypercholesterolemia (HoFH) Market refers to the global industry focused on developing, manufacturing, and commercializing therapies, diagnostics, and treatment solutions for HoFH a rare genetic disorder causing extremely high LDL cholesterol levels from birth. The market includes pharmaceutical drugs, gene therapies, lipid-lowering treatments, and medical devices aimed at managing cardiovascular risks in affected patients.

Recent Key Developments of United States:

✅ December 2025: FDA fast-tracked a gene therapy candidate from Verve Therapeutics for HoFH, driven by successful early trial results in pediatric cohorts.

✅ November 2025: Amgen reported positive Phase 3 data for olpasiran in HoFH subsets at the American Heart Association meeting, signaling potential label expansion by mid-2026.

✅ October 2025: Regeneron expanded access to Evkeeza (evinacumab) through new reimbursement agreements with major US payers, improving affordability for HoFH patients amid rising diagnosis rates.

Recent Key Developments of Japan:

✅ December 2025: Local adoption of lipid apheresis surged following new guidelines from the Japan Atherosclerosis Society, supported by government subsidies for rural access.

✅ November 2025: Ionis Pharmaceuticals partnered with a Tokyo-based biotech for pharmacogenomic testing in HoFH, aiming to personalize lomitapide dosing nationwide.

✅ October 2025: Japanese health ministry approved expanded indications for Novartis' Leqvio in lipid clinics, boosting HoFH screening integration into national cardiology programs.

List of the Key Players in the Homozygous Familial Hypercholesterolemia Market:

AstraZeneca
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Accord Healthcare
Changzhou Pharmaceutical Factory
Regeneron Pharmaceuticals, Inc.
Amryt Pharma plc
Amgen Inc.
Organon Global Inc.
CMP Pharma

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/homozygous-familial-hypercholesterolemia-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Homozygous Familial Hypercholesterolemia Market:

By Drug Class: Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors.

By Route of Administration: Oral, Parenteral, Nasal.

By Technology: CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies.

By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=homozygous-familial-hypercholesterolemia-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Homozygous Familial Hypercholesterolemia market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Homozygous Familial Hypercholesterolemia Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Homozygous Familial Hypercholesterolemia market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Homozygous Familial Hypercholesterolemia Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Homozygous Familial Hypercholesterolemia Market in 2025?
◆ What is the projected growth rate of the Homozygous Familial Hypercholesterolemia Market through 2033?
◆ Who are the key players in the Homozygous Familial Hypercholesterolemia Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.